Study of Low-Dose Digoxin Added to Standard Treatment for Adults With Heart Failure After Acute Decompensation

What this Trial Is About

Researchers are evaluating whether adding low-dose digoxin to standard medical treatment improves the clinical status and quality of life for adults with heart failure with reduced ejection fraction HFrEF who have recently stabilized after an acute episode. This randomized, controlled, open-label study focuses on patients who were hospitalized or treated urgently for heart failure decompensation. The main goal is to see if digoxin increases the proportion of patients who are Alive and Well at 180 days, based on a quality-of-life questionnaire score. Participants are randomly assigned to receive either usual care alone or usual care plus low-dose oral digoxin. Digoxin dosing is carefully adjusted using a web-based calculator based on kidney function to keep levels low and consistent with safety guidelines. The study compares these two groups over a period of 180 days following stabilization after acute heart failure. During the study, participants will undergo assessments including quality-of-life questionnaires, symptom evaluations, and functional capacity tests like the 6-minute walk test. Researchers will also measure biomarkers related to heart failure and kidney function and track major cardiovascular events such as hospitalizations or urgent care visits. The study aims to provide evidence on the role of low-dose digoxin in modern heart failure management and will last for at least 180 days of follow-up after enrollment.

Digoxin After Acute Heart Failure (DIG-DICA)